疾病修饰治疗对儿科发病多发性硬化症 (POMS) 的认知能力的影响
Ashley M Whitaker1, Emily Zhou2, Brooke K Iwamoto3
1Phoenix Children's Hospital, United States; Keck School of Medicine, University of Southern California, United States.
Multiple sclerosis and related disorders
|March 7, 2026
概括
针对儿科多发性硬化症 (MS) 的疾病修饰疗法 (DMT) 显示出各种各样的认知效应. 与Natalizumab不同的是,B细胞枯竭和二甲基烟酸治疗与平均或更好的认知功能有关.
科学领域:
- 神经学 神经学
- 儿科神经学 儿科神经学
- 神经免疫学 神经免疫学
背景情况:
- 儿科发病多发性硬化症 (POMS) 带来了认知方面的挑战.
- 疾病修饰疗法 (DMT) 可能通过减缓进展来改善POMS中的认知能力.
- 关于DMT对儿童认知影响的研究有限.
研究的目的:
- 评估儿童多发性硬化症患者的认知能力,这些患者接受了DMTs治疗.
- 在POMS中比较不同DMT的认知结果.
- 调查DMT与患有MS的儿童认知功能之间的关系.
主要方法:
- 对26名POMS患者的横截面研究 (诊断时的平均年龄为14.6岁).
- 治疗组包括二甲基烟酸,纳塔利祖马布和B细胞枯竭疗法.
- 用数字跨度 (DS) 和快速自动命名 (RAN) 测量注意力/工作记忆 (WM) 和处理速度 (PS) 的认知结果.
主要成果:
- 整体WM和PS得分是临床平均值 (WM x̄=8.7,PS x̄=8.5).
- 在DMT组之间观察到PS (RAN) 的显著差异 (F(2,23) =7.9,p=0.002).
- 纳塔利祖马布组表现低于平均水平 (DS x̄=6.8,RAN x̄=5.8),而二甲基烟酸和B细胞枯竭组表现在平均范围内.
结论:
- B细胞枯竭疗法与平均至高平均认知表现相关.
- 丁甲基烟酸治疗显示出变化,但平均值在正常认知范围内.
- 纳塔利祖马布治疗与低平均水平至低于平均水平的认知评分有关,这表明二甲基烟酸和B细胞枯竭可能更有益.
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Development During Adulthood
1.0K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.0K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Negative and Cognitive Symptoms of Schizophrenia
842
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
842
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
766
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
766
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K


